Market closed

FibroGen/$FGEN

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About FibroGen

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

Ticker

$FGEN
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
San Francisco, United States

Employees

486
Website
www.fibrogen.com

FibroGen Metrics

BasicAdvanced
$59M
-
-$1.22
0.73
-

$59M

0.73

$2.93

$0.18

1.4M

1.283

0.975

-45.456

-46.097

-6.00%

-20.53%

76.86%

0.325

-0.24

-0.24

-0.464

16.15%

-59.96%

-14.08%

-19.34%

What the Analysts think about FibroGen

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for FibroGen stock.

FibroGen Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

FibroGen Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

FibroGen News

AllArticlesVideos
FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen Appoints David DeLucia as Chief Financial Officer

GlobeNewsWire·4 weeks ago
FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

Seeking Alpha·2 months ago
FibroGen Reports Third Quarter 2024 Financial Results

FibroGen Reports Third Quarter 2024 Financial Results

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $FGEN

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for FibroGen stock?

FibroGen (FGEN) has a market cap of $59M as of January 15, 2025.

What is the P/E ratio for FibroGen stock?

The price to earnings (P/E) ratio for FibroGen (FGEN) stock is 0 as of January 15, 2025.

Does FibroGen stock pay dividends?

No, FibroGen (FGEN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next FibroGen dividend payment date?

FibroGen (FGEN) stock does not pay dividends to its shareholders.

What is the beta indicator for FibroGen?

FibroGen (FGEN) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.